Targeted Immunotherapy: An Update with Special Emphasis on Ovarian Cancer

References

• Berek J S, Knapp R C, Malkasian G D, et al. CA 125 levels correlated with second look operations among ovarian cancer patients. Obstet Gynecol 1986; 67: 686
   Google Scholar
• Silverberg E, Boring C C, Squires T S. Cancer statistics 1990. CA Cancer J Clin 1990; 40: 9
   PubMed Web of Science ®Google Scholar
• Hoskins W J. The role of cytoreductive surgery in overain cancer. Cancer Principles and Practice of Oncology, V T DeVita, Jr, S Hellman, S A Rosenberg. J. B. Lippincott, Philadelphia 1987
   Google Scholar
• Howel S, Kirmani S, McClay E, Kim S, Braly P, Plaxe S. Intraperitoneal cisplatinum-based chemotherapy for ovarian carcinoma. Semin Oncol 1991; 18((suppl. 3))5
   Google Scholar
• Navoli M, Cognetti F, et al. Intraperitoneal recombinant alpha-2-interferon: Alternation with cisplatin as salvage therapy for minimal residual-disease ovarian cancer: A phase II study. J Clin Oncol 1990; 8: 1036
   Google Scholar
• Spanos W J, Jr, Day T, Abner A, et al. Complications in the use of intrabdominal 32P for ovarian carcinoma. Gynecol Oncol 1992; 45: 243
   Google Scholar
• Berek J S, Knapp R C, Hacker N F, et al. Intraperitoneal immunotherapy of epithelial ovarian carcinoma with coryno-bacterium parvum. Am J Obstet Gynecol 1985; 152: 1003
   PubMedGoogle Scholar
• Epenetos A A, Munro A J, Stewart S, et al. Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies. J Clin Oncol 1987; 5: 1890
   PubMed Web of Science ®Google Scholar
• DeNardo G L, DeNardo S J, Lamborn K R, Van Hoosear K A, Kroger L A. Enhancement of tumour uptake of monoclonal antibody in nude mice with PEG IL-2 Antibody Immunocon-jugates and Radiopharmaceuticals 1991; 4: 859
   Google Scholar
• Pimm M V. An examination of the influence of vasoactive drugs on blood flow and localisation of a monoclonal antibody in human tumour xerografts. Br J Cancer 1990; 62: 69
   Google Scholar
• Ito T, Griffin T W, Collins J A, et al. Intratumoral and whole body distribution of Cl 10 anti-carcinoembryonic antigen radiommunotoxin after intraperitoneal and intravenous injection: Quantitative autoradiographic study. Cancer Res. 1992; 52: 1961
   PubMed Web of Science ®Google Scholar
• Pectasides D, Stewart S, Courtney-Luck N, et al. Antibody guided irradiation of malignant pleural and pericardial effusions. Br J Cancer 1986; 53: 1463
   Google Scholar
• Haisma H J, Pinedo H M, Kessel M AP, et al. Human IgM monoclonal antibody 16.88: Pharmacokinetics and immuno-genicity in colorectal cancer patients. J Natl Cancer Inst 1991; 83: 1813
   Google Scholar
• Brown S L, Miller R A, Horning S J, et al. Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combinatibn with alpha interferon. Blood 1989; 73: 651
   PubMed Web of Science ®Google Scholar
• Press O W, Eary J F, Badger C C, et al. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-I (anti-CD37) antibody. J Clin Oncol 1989; 7: 1027
   PubMed Web of Science ®Google Scholar
• Grossbard M L, Freedom A S, Ritz J, et al. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: A phase I trial of daily bolus infusion. Blood 1992; 79: 576
   PubMed Web of Science ®Google Scholar
• Diehl L F, Penny D M, Terebelo H, et al. Radiation as salvage therapy for patients with Hodgkin's disease relapsing after MOPP chemotherapy. Cancer Treat Res 1983; 67: 827
   Google Scholar
• Duvall E, Wyllie A H. Death and the cell. lrnmunol Today 1986; 7: 115
   PubMedGoogle Scholar
• Vriesendorp H M, Herpst J M, Germack M A, et al. Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease. including Radiation Therapy Oncology Group 87-01. J Clin Oncol 1991; 9: 918
   PubMed Web of Science ®Google Scholar
• Jain R K. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in turnours. Cancer Res 1990; 50: 814
   PubMed Web of Science ®Google Scholar
• Dippold W, Bernhard H. Immunorecognition of ganglioside epitopes: Correlation between affinity and cytotoxicity of ganglioside antibodies. Eur J Cancer 1992; 10: 1605
   Google Scholar
• Sung C, Shockley T R, Morrison P F, et al. Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid turnours. Cancer Res 1992; 52: 377
   PubMed Web of Science ®Google Scholar
• Johnson D A, Barton R L, Fix D V, et al. Induction of im-munogenicity of monoclonal antibodies by conjugation with drugs. Cancer Res 1991; 51: 5774
   PubMed Web of Science ®Google Scholar
• Goldenberg D M. Radioimmunotherapy of cancer: Arming the missiles. J Nucl Med 1992; 33: 1110
   PubMed Web of Science ®Google Scholar
• Sivolapenko G B, Kalofonos H P, Stewart J SW, Hird V, Epenetos A A. Pharmacokinetics of radiolabelled murine monoclonal antibodies administered intravenously and intraperitoneally to patients with cancer for diagnosis and therapy. J Pharm Med 1992; 2: 155
   Google Scholar
• Kaminski M S, Kitamura K, Maloney D G, et al. Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B-cell lymphoma. A study of hybridoma class switch variants. J Immunol 1986; 136: 1123
   PubMed Web of Science ®Google Scholar
• Mujoo K, Cheresh D A, Yang H M, Reisfeld R A. Disialgan-glioside GD2 on human neuroblastoma cells: Target antigen for monoclonal antibody-mediated cytolysis and suppression of tumour growth. Cancer Res 1987; 47: 1098
   PubMed Web of Science ®Google Scholar
• Trauth B C, Klas C, Peters A MJ, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 301
   PubMed Web of Science ®Google Scholar
• Drebin J A, Link V C, Greene M I. Monoclonal antibodies for the neu oncogene product directly mediate anti-tumour effects in vivo. Oncogene 1988; 2: 387
   PubMed Web of Science ®Google Scholar
• Foxwell B MJ, Band H A, Long J, et al. Conjugation of monoclonal antibodies to a synthetic peptide substrate for protein kinase: a method of labeling antibodies with 32P. Br J Cancer 1988; 57: 489
   PubMed Web of Science ®Google Scholar
• Wessels B W, Rogus R D. Radionuclide selection and model absorbed dose calculations for radiolabeled tumour associated antibodies. Med Phys 1988; 11: 638
   Google Scholar
• Wheldon T E, Odonoghue J A. The radiobiology of targeted radiotherapy. Int J Radiat Biol 1990; 58: 1
   PubMed Web of Science ®Google Scholar
• Wheldon T E, O'Donoghue J A, Barett J, Michalowski A S. The curability of tumours of differing size by targeted radiotherapy using 131I or 90Y. Radiother Oncol 1991; 21: 91
   PubMed Web of Science ®Google Scholar
• Langmuir V K, Mendonca H L, Vanderheyden J L, Fu-Min Su. Comparisons of the efficacy of 186Re- and 131I-labeled antibody in multicell spheroids. Int J Radiat Oncol Biol Phys 1992; 24: 127
   Google Scholar
• Bardies M, Lame J, Meyers M J, et al. A simplified approach to beta dosimetry for small spheres labeled on the surface. Phys Med Biol 1990; 35: 1039
   PubMed Web of Science ®Google Scholar
• Boniface G R, Izard M E, Walker K Z, et al. Labeling of monoclonal antibodies with samarium-153 for combined ra-dioimmunoscintigraphy and radioimmunotherapy. J Nucl Med 1989; 30: 683
   Google Scholar
• Stewart J SW, Hird V, Snook D, et al. Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer. J Clin Oncol 1990; 8: 1941
   PubMed Web of Science ®Google Scholar
• Ballantyne K C, Perkins A C, Pimm M V, et al. Biodistribution of a monoclonal antibody-methotrexate conjugate (791T/36-MTX) in patients with colorectal cancer. Int J Cancer 1988; 42((suppl. 2))103
   Google Scholar
• Bosslet K, Steinstrasser A, Hermentin P, et al. Generation of bispecific monoclonal antibodies for two phase radioimmunotherapy. Br J Cancer 1991; 63: 681
   Google Scholar
• Mezzanzanica D, Garrido M A, Neblock D S, et al. Human T-lymphocytes targeted against an established human ovarian carcinoma with a bispecific F(ab')2 antibody prolong host survival in a murine xenograft model. Cancer Res 1991; 51: 5716
   PubMed Web of Science ®Google Scholar
• Ferrini S, Prigione I, Miotti S, et al. Bispecific monoclonal antibodies directed to CD 16 and to tumor-associated antigen induce target-lysis by resting N K cells and by a subset of N K clones. Int J Cancer 1991; 48: 227
   Google Scholar
• Paganelli G, Malcovati M, Fazio F. Monoclonal antibody pretargetting techniques for tumour localisation: the avidin-biotin system. Nucl Med Commun 1991; 12: 211
   PubMed Web of Science ®Google Scholar
• Paganelli G, Magnani P, Zito F, et al. Three-step monoclonal antibody tumour targeting in carcinoembryonic antigen-positive patients. Cancer Res 1991; 51: 5960
   PubMed Web of Science ®Google Scholar
• Haisma H J, Boven E, van Muijen M, et al. Analysis of a conjugate between anticarcinembryonic antigen monoclonal antibody and alkaline phosphatase for specific activation of the prodrug etoposide phosphate. Cancer Immunol Im-munother 1991; 34: 343
   Google Scholar
• Matzku S, Brocker E-B, Bruggen J, Dippold W G, Tilgen W. Models of binding and internalisation of monoclonal antibodies to human melanoma cell lines. Cancer Res 1986; 46: 3848
   PubMed Web of Science ®Google Scholar
• Bender H, Takahashi H, Adachi K, et al. Immunotherapy of human glioma xenografts with unlabeled, 131I-, or 125I labeled monoclonal antibody 425 to epidermal growth factor receptor. Cancer Res 1992; 52: 121
   PubMed Web of Science ®Google Scholar
• Schlom J, Eggenspeger D, Colcer D, et al. Therapeutic advantage of high affinity anticarcinoma radioimmuno-conjugates. Cancer Res 1992; 52: 1067
   PubMed Web of Science ®Google Scholar
• Scheinberg D A, Strand M. Radioimmunotherapy in experimental animal models: Principles derived from models. Cancer Res 1990; 50: 962s
   Google Scholar
• Fowler J F. Radiobiological aspects of low dose rates in radioimmunotherapy. Int J Radiat Oncol Biol Phys 1990; 18: 1261
   PubMed Web of Science ®Google Scholar
• Stone M, Amlot P, Fay J, et al. Immunotoxin therapy of B-cell lymphoma. Blood 1990; 76: 374
   Web of Science ®Google Scholar
• Spitler L E, Mischak R, Scannon R. Therapy of metastatic malignant melanoma using xomazyme mel, a murine monoclonal anti-melanoma ricin A chain immunotoxin. Nucl Med Biol 1991; 16: 625
   Google Scholar
• Durrant L G, Byers V S, Scannon P J. Humoral immune responses to XMMCO-791-RTA immunotoxin in colorectal cancer patients. Clin Exp Immunol 1989; 75: 258
   PubMed Web of Science ®Google Scholar
• Order S E, Stillwagon G B, Klein J L, et al. Iodine-131 anti-ferritin: a new treatment modality in hepatoma: a Radiation Therapy Oncology Group Study. J Clin Oncol 1985; 3: 1573
   PubMed Web of Science ®Google Scholar
• Riva P, Marangolo M, Tison V, et al. Treatment of metastatic colorectal cancer by means of specific monoclonal antibodies conjugated with iodine-131: a phase II study. Nucl Med Biol 1991; 18: 1109
   Google Scholar
• Kosmas C, Snook D, Gooden C S, et al. Development of humoral immune responses against a macrocycle chelating agent (DOTA) in cancer patients receiving radioimmuno-conjugates for imaging and therapy. Cancer Res 1992; 52: 904
   PubMed Web of Science ®Google Scholar
• Hird V, Snook D, Kosmas C, . Intraperitoneal radioimmunotherapy with yttrium-90-labeled immunoconjugates monoclonal antibodies. Applications in clinical oncology, A A Epenetos, et al. Chapman & Hall, London 1991; 267–71
   Google Scholar
• Steinitz M, Tamir S, Frödin J E, Lelvert A K, Mellstedt H. Human monoclonal anti-idiotypic antibodies. I. Establishment of immortalized cell lines from a tumor patient treated with mouse monoclonal antibodies. J Immunol 1988; 141: 3516
   PubMed Web of Science ®Google Scholar
• Lamki L, Kavanagh J, Rosenblum M, et al. Radioimmunotherapy of ovarian cancer with intraperitoneal 90Y-B72.3 with and without EDTA scavengers in advances in the applications of monoclonal antibodies in clinical oncology. 8th International Hammersmith Meeting. 1992
   Google Scholar
• Muto M G, Finkler N J, Kassis A I, et al. Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-31 labeled monoclonal antibody OC125. Gynecol Oncol 1992; 45: 265
   PubMed Web of Science ®Google Scholar
• Colcher D, Esteban J, Carrasquillo J A, et al. Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma. Cancer Res 1987; 47: 4218
   PubMed Web of Science ®Google Scholar
• Malamitsi J, Skarlos D, Fotiou S, et al. Intracavitary use of two radiolabeled tumor-associated monoclonal antibodies. J Nucl Med 1988; 29: 1910
   PubMed Web of Science ®Google Scholar
• Breitz H B, Weiden P L, Vanderheyden J L, et al. Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: Results of phase I trials. J Nucl Med 1992; 33: 1099
   PubMed Web of Science ®Google Scholar
• Pai L H, Bookman M A, Ozols R S. Clinical evaluation of intraperitioneal pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. J Clin Oncol 1991; 9: 2095
   PubMed Web of Science ®Google Scholar
• Maraveyas A, Snook D, Hird V, et al. Pharmacokinetic and toxicity of an yttrium-90-CITC-DTPA-HMFG l radio-immunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer. Cancer 1993, (in press)
   Google Scholar
• Hird V, Maraveyas A, Snook D, et al. Adjuvant therapy of ovarian cancer with a radioactive monoclonal antibody. Br J Cancer 1993, (in press)
   Google Scholar